ICSI

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Episcopal conference, American College, Woman, Infertility, Insemination, Health, ICSI, IVF, ACOG, Booth, IUI

With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.

Key Points: 
  • With the addition of new team members to its commercial team in key strategic geographical locations, Femasys is poised to fully initiate its strategic initiatives and execute on its delivery of innovative, accessible options to impact women’s healthcare.
  • The newly appointed team brings together seasoned professionals with a wealth of commercial experience across various sectors of the healthcare industry.
  • Their collective expertise plays a pivotal role in driving Femasys' commercial efforts forward to realize the Company’s strategic vision, with initial emphasis on the Company’s infertility portfolio, led by the FemaSeed® product.
  • The 2024 ACOG meeting presents an ideal opportunity for Femasys to showcase the strength of its initial commercial team and its commitment to shaping the future of women's healthcare.

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
Samstag, Mai 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

In Vitro Fertilization Market Projected to Reach US$ 1,940.8 Million Valuation by 2034: Future Market Insights, Inc.

Retrieved on: 
Dienstag, April 30, 2024
Online, Merck Group, Nature, Area studies, Hope, MHealth, Hospital, Publication, News, Uday Chopra, Health care, ICSI, Research, Medication, Growth, IVF, Medical device, Social Problems, Cryopreservation, Fertilisation, Associate, Journal, FMI, Competitive intelligence, Pet industry

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The in vitro fertilization market is on its way to perceive a surge in valuation, from US$ 1.50 billion in 2024 up to US$ 4.80 billion by 2034. FMI report indicates a healthy CAGR of 12.30% between 2024 and 2034, reckoning an influential IVF market growth.

Key Points: 
  • The breath analyzers market is poised for steady growth, with a projected CAGR of 4.9% from 2024 to 2034.
  • By 2034, the market is expected to reach a valuation of US$ 1,154.3 million, reflecting significant expansion.
  • The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.
  • Sales of donor egg IVF are projected to reach US$ 7,159.50 million by 2034, with a robust CAGR of 7.90% between 2024 and 2034.

GenEmbryomics and Progenesis Announce Strategic Partnership to Transform IVF Testing

Retrieved on: 
Mittwoch, April 24, 2024
DSM-IV codes, Genomics, PGT, Infertility, ICSI, Partnership, Fertility, Parent, Science, Genetic testing, IVF, Patient, Diagnosis, MBA, Whole genome sequencing, Reproductive medicine

Through this partnership, GenEmbryomics and Progenesis will join forces to offer the powerful benefits of preimplantation genetic testing with whole genome sequencing (PGT-WGS) to fertility patients.

Key Points: 
  • Through this partnership, GenEmbryomics and Progenesis will join forces to offer the powerful benefits of preimplantation genetic testing with whole genome sequencing (PGT-WGS) to fertility patients.
  • Progenesis will leverage its state-of-the-art laboratory and facilities, while GenEmbryomics will serve as the preferred provider of its Panacea-GenomeScreen™ PGT-WGS test, the first and only comprehensive PGT-WGS embryo genetic test.
  • "Partnering with GenEmbryomics marks a pivotal step in our unwavering commitment to providing the premier IVF testing service," said Nabil Arrach, Ph.D., MBA, CEO of Progenesis.
  • "We are ecstatic to partner with Progenesis, a leader in IVF whose track-record in making IVF testing available to everyone speaks for itself," said Nick Murphy, Ph.D., Managing Director of GenEmbryomics.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on: 
Mittwoch, März 20, 2024
Infertility, TMSC, Pregnancy rate, IVF, IUI, Pregnancy, Fertilisation, Woman, Male, Safety, Literature, FDA, ICSI, Insemination, Physician, Birth control

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
  • “These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
  • “The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
  • The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

China In-Vitro Fertilization Market Research Report 2023-2030 Featuring Vitrolife, Cloudnine, Nova IVI Fertility, Monash, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono - ResearchAndMarkets.com

Retrieved on: 
Freitag, März 22, 2024
General Health, Other Health, Consumer, Health, Baby, Maternity, Consciousness, Infertility, Prevalence, IVF, Sterilization, Fertility, Fertilisation, Woman, Male, Infection, Patient safety, ICSI, Birth control

Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.

Key Points: 
  • Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.
  • Disposable devices are predicted to be among the instruments used considerably in the China In-Vitro Fertilization (IVF) market.
  • ICSI IVF is foreseen to be among the considerably utilized processes in the China In-Vitro Fertilization (IVF) market.
  • Fertility clinics are projected to experience a considerable increase in utilization in the China In-Vitro Fertilization (IVF) market.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Mittwoch, März 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Retrieved on: 
Mittwoch, Februar 28, 2024
ICSI, IVF, Woman, Lead, Fertilisation, Risk

ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). FemaSeed has been designed to deliver sperm reliably and safely, directly into the fallopian tube where conception occurs.

Key Points: 
  • -- Femasys readies for the commercial launch of FemaSeed® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) --
    ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
  • FemaSeed has been designed to deliver sperm reliably and safely, directly into the fallopian tube where conception occurs.
  • “Femasys remains committed to providing accessible and affordable options and the timing of FemaSeed’s launch is particularly relevant given the uncertainty following the Alabama Supreme Court ruling on February 16th.
  • Following our substantial cash infusion in the fourth quarter 2023, we are now funded into the second half of 2025 and on track to make FemaSeed, available later this year to women and their doctors, as a first-line treatment option that does not involve handling of embryos,” said Femasys’ CEO Kathy Lee-Sepsick.

Sonata Software: International Services delivered Industry leading Dollar revenue growth; up 3.5% QoQ (38.3% YoY); Domestic business delivered strong Gross contribution growth of 14.2% QoQ (25.8% YoY) in INR

Retrieved on: 
Donnerstag, Februar 1, 2024
Growth, DSO, ICSI, Quarter, BFSI, International, MD, USD, Digital, Workplace, INR, SSNA, Management, Microsoft, TTH, PAT, Quant, Acquisition, Yoy, Health care, TMT, Pension fund

The Company has re-measured the fair value of the contingent consideration payable to be USD 105.42 mn (INR 87,719 Lakhs), thereby an increase of USD 17.12 mn (INR 14,244 Lakhs).

Key Points: 
  • The Company has re-measured the fair value of the contingent consideration payable to be USD 105.42 mn (INR 87,719 Lakhs), thereby an increase of USD 17.12 mn (INR 14,244 Lakhs).
  • Our International services Revenue in USD terms grew 3.5% QoQ and Domestic Gross contribution grew by 14.2% QoQ.
  • Performance Highlights for the quarter:
    Revenues at ₹ 2,493.4 crores; QoQ growth of 30%
    EBITDA at ₹ 227.2 crores; QoQ growth of 3%
    PAT before exceptional item stood at ₹ 128.5 Crores; QoQ growth of 3%.
  • Revenues at ₹ 1,800.3 crores; QoQ growth of 45%
    EBITDA at ₹ 59.2 crores; QoQ growth of 5%
    PAT at ₹ 42.6 crores; QoQ growth of 5%
    DSO at 36 days (Q2'24: 35 days).

Sonata Software: International Services delivered Industry leading Dollar revenue growth; up 3.5% QoQ (38.3% YoY); Domestic business delivered strong Gross contribution growth of 14.2% QoQ (25.8% YoY) in INR

Retrieved on: 
Donnerstag, Februar 1, 2024
Growth, DSO, ICSI, Quarter, BFSI, International, MD, USD, Digital, Workplace, INR, SSNA, Management, Microsoft, TTH, PAT, Quant, Acquisition, Yoy, Health care, TMT, Pension fund

The Company has re-measured the fair value of the contingent consideration payable to be USD 105.42 mn (INR 87,719 Lakhs), thereby an increase of USD 17.12 mn (INR 14,244 Lakhs).

Key Points: 
  • The Company has re-measured the fair value of the contingent consideration payable to be USD 105.42 mn (INR 87,719 Lakhs), thereby an increase of USD 17.12 mn (INR 14,244 Lakhs).
  • Our International services Revenue in USD terms grew 3.5% QoQ and Domestic Gross contribution grew by 14.2% QoQ.
  • Performance Highlights for the quarter:
    Revenues at ₹ 2,493.4 crores; QoQ growth of 30%
    EBITDA at ₹ 227.2 crores; QoQ growth of 3%
    PAT before exceptional item stood at ₹ 128.5 Crores; QoQ growth of 3%.
  • Revenues at ₹ 1,800.3 crores; QoQ growth of 45%
    EBITDA at ₹ 59.2 crores; QoQ growth of 5%
    PAT at ₹ 42.6 crores; QoQ growth of 5%
    DSO at 36 days (Q2'24: 35 days).